You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Gemtuzumab

Showing 1 - 25 of 112
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial in Baltimore (Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Dose Escalation -tagraxofusp-erzs
  • Dose Expansion at RP2D -tagraxofusp-erzs
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 27, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Baltimore, Maryland
  • +1 more
Dec 13, 2022

Acute Myeloid Leukemia Trial in Tampa (Vyxeos, Gemtuzumab Ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Sep 23, 2022

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Sep 26, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Acute Myeloid Leukemia Trial in Heidelberg (Gemtuzumab Ozogamicin 147, Gemtuzumab Ozogamicin 1, Glasdegib)

Terminated
  • Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin 147
  • +3 more
  • Heidelberg, Baden-Württemberg, Germany
    University Hospital Heidelberg, Internal Medicine V
Jun 27, 2022

Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 10, 2022

Leukemia, Myeloid, Acute Trial in Jerusalem (Vyxeos, Mylotarg)

Recruiting
  • Leukemia, Myeloid, Acute
  • Jerusalem, Yerushalayim, Israel
    Shaare Zedek Medical Center
Oct 25, 2022

Acute Myeloid Leukemia Trial in Pittsburgh (mitoxantrone + etoposide + gemtuzumab ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • mitoxantrone + etoposide + gemtuzumab ozogamicin
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 9, 2022

Acute Myeloid Leukemia Trial in Memphis (Venetoclax, Azacitidine, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jul 21, 2023

Acute Myeloid Leukemia Trial in Germany (Venetoclax plus Azacitidine, standard of care chemo plus gemtuzumab ozogamicin)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Venetoclax plus Azacitidine
  • standard of care chemotherapy plus gemtuzumab ozogamicin
  • Essen, NRW, Germany
  • +17 more
Jun 6, 2023

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Nov 11, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Acute Myeloid Leukemia Trial in Baltimore, Houston (Atovaquone, Cytarabine, Daunorubicin)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Baltimore, Maryland
  • +1 more
Oct 7, 2022

Acute Myeloid Leukemia Trial in New York (CPX-351, Gemtuzumab Ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • New York, New York
    Weill Cornell Medical College
Dec 21, 2021

Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
  • Gemtuzumab Ozogamicin
  • Dresden, Germany
  • +1 more
Dec 20, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +3 more
  • Gemtuzumab Ozogamicin
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Houston, Texas
    M D Anderson Cancer Center
Jun 2, 2021

ECG, Pharmacokinetics, Safety Trial in Worldwide (Gemtuzumab Ozogamicin)

Completed
Has Results
  • ECG
  • +2 more
  • Gemtuzumab Ozogamicin
  • Augusta, Georgia
  • +23 more
Feb 28, 2022

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute

Recruiting
  • Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2021

Leukemia, Myeloid, Acute Trial in Canada, United States (VOR33, Mylotarg)

Recruiting
  • Leukemia, Myeloid, Acute
  • La Jolla, California
  • +8 more
Jan 31, 2023

Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow

Recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2022

Acute Myeloid Leukemia Trial in Germany (MODULE: conventional chemo (Cytarabine+Daunorubicin) in combination with

Active, not recruiting
  • Acute Myeloid Leukemia
  • MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO
  • +4 more
  • München, Bayern, Germany
  • +10 more
Aug 31, 2021

Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia Trial in New York (Fludarabine, Busulfan,

Completed
  • Acute Myelogenous Leukemia
  • +2 more
  • New York, New York
    Columbia University Medical Center
Aug 4, 2021

Acute Myeloid Leukemia Trial in Austria, Germany (Gemtuzumab Ozogamicin (Mylotarg), standard chemo)

Completed
  • Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin (Mylotarg)
  • standard chemotherapy
  • Graz, Austria
  • +59 more
Sep 28, 2021

Patients Diagnosed With Acute Myeloid Leukemia Who Received

Completed
Has Results
  • Leukemia, Myeloid, Acute
  • Gemtuzumab Ozogamicin
  • New York, New York
    Pfizer Investigational Site
Jul 16, 2021